EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial

Malin Erika Carmland iD, Melissa Dall Kreutzfeldt, Jakob Vormstrup Holbech iD, Peter Kolind Brask-Thomsen iD, Thomas Krøigård iD, Peter Nørregaard Hansen, Hatice Tankisi, Troels Staehelin Jensen iD, Flemming Winther Bach iD, Søren Hein Sindrup iD, Nanna Brix Finnerup iD

European Journal of Pain · 2024-01 · 28 (1) · 105-119

DOI: 10.1002/ejp.2165 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Pain, online erschienen am 11.08.2023. Verfasst von Malin Erika Carmland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. Hauptthemen laut MEDLINE: Neuralgia. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuropathic pain is common and difficult to treat. The sodium channel blocker lacosamide is efficacious in animal models of pain, but its effect on neuropathic pain in humans is inconclusive.

Methods

In a multicentre, randomized, double‐blinded placebo‐controlled phenotype stratified trial, we examined if lacosamide produced better pain relief in patients with the irritable nociceptor phenotype compared to those without. The primary outcome was the change in daily average pain from baseline to last week of 12 weeks of treatment. Secondary and tertiary outcomes included pain relief, patient global impression of change and presence of 30% and 50% pain reduction.

Results

The study was prematurely closed with 93 patients included and 63 randomized to lacosamide or placebo in a 2:1 ratio, of which 49 fulfilled the per protocol criteria and was used for the primary objective. We did not find a better effect of lacosamide in patients with the irritable nociceptor phenotype, the 95% CI for the primary objective was 0.41 (−1.2 to 2.0). For all patients randomized, lacosamide had no effect on the primary outcome, but significantly more patients were responders to lacosamide than during placebo, with an NNT of 4.0 (95% CI 2.3–16.1) and 5.0 (95% CI 2.8–24.5) for 30% and 50% pain reduction respectively. We did not identify any predictors for response. Lacosamide was generally well tolerated.

Conclusion

We could not confirm that lacosamide was more efficacious in patients with the irritable nociceptor type, but the study was prematurely closed, so we cannot exclude a small difference. Significance Treatment of neuropathic pain is often a trial and error process. Little is known about which patient benefit from which kind of medication. The sodium channel blocker lacosamide shows variable effect on neuropathic pain. Pain sensory phenotype, as defined by quantitative sensory testing, did not predict response to treatment with lacosamide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuralgiaHumansLacosamidePain MeasurementDouble-Blind MethodTreatment OutcomeSodium Channel BlockersPhenotype

Substanzen

LacosamideSodium Channel Blockers

Autor:innen und Institutionen

  • Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
  • Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Neurology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

ORCID-Profile: Malin Erika Carmland, Jakob Vormstrup Holbech, Peter Kolind Brask-Thomsen, Thomas Krøigård, Troels Staehelin Jensen, Flemming Winther Bach, Søren Hein Sindrup, Nanna Brix Finnerup

Zitieren

APA

Carmland, M. E., Kreutzfeldt, M. D., Holbech, J. V., Brask-Thomsen, P. K., Krøigård, T., Hansen, P. N., Tankisi, H., Jensen, T. S., Bach, F. W., Sindrup, S. H., & Finnerup, N. B. (2024). The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial. European Journal of Pain, 28(1), 105-119. https://doi.org/10.1002/ejp.2165

Vancouver

Carmland ME, Kreutzfeldt MD, Holbech JV, Brask-Thomsen PK, Krøigård T, Hansen PN, et al. The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial. European Journal of Pain. 2024;28(1):105-119. doi:10.1002/ejp.2165

BibTeX
@article{Carmland2024,
  author = {Carmland, Malin Erika and Kreutzfeldt, Melissa Dall and Holbech, Jakob Vormstrup and Brask-Thomsen, Peter Kolind and Krøigård, Thomas and Hansen, Peter Nørregaard and Tankisi, Hatice and Jensen, Troels Staehelin and Bach, Flemming Winther and Sindrup, Søren Hein and Finnerup, Nanna Brix},
  title = {The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial},
  journal = {European Journal of Pain},
  year = {2024},
  volume = {28},
  number = {1},
  pages = {105--119},
  doi = {10.1002/ejp.2165}
}
Kostenlos starten →